Report findsĀ nirsevimabĀ 80% effective at preventing RSV-associatedĀ ICU admissionsĀ
Nirsevimab was found to be 80% effective at preventing respiratory syncytial virus-associated intensive care unit admissions during the 2024-2025 RSV season, according to a Centers for Disease Control and Prevention report released Nov. 20. It also found the treatment to be 83% effective at preventing acute respiratory failure among infants admitted to an ICU with symptoms during their first RSV season. āThese estimates support the recommendation for use of nirsevimab as a prevention strategy to protect infants against severe outcomes from RSV infection,ā the CDC said.
Related News Articles
Chairperson's File
A career in healthcare is rewarding yet challenging. Through every day and every shift, healthcare professionals help patients and families navigate what couldā¦
Headline
The Food and Drug Administration has approved a blood test for detecting Alzheimerās by Roche and Eli Lilly, according to an announcement Aug. 24 by Roche. Theā¦
Headline
The Department of Health and Human Services Aug. 18 announced that its Administration for Children and Families has added two new peer support programs to theā¦
Perspective
May is Mental Health Awareness Month, a time to elevate a conversation that hospitals and health systems live every day. Behavioral health is inseparable fromā¦
Headline
The Agency for Healthcare Research and Quality has issued a request for nominations for candidates to serve on the U.S. Preventive Services Task Force. Whileā¦
Headline
Obesity rates for U.S. children and teenagers have reached record highs, while rates for adults had a slight decline, according to reports by the Centers forā¦